Form 4: Royalty Pharma Director Vlad Coric Receives Stock Award

Director Vlad Coric received 3,184 Class A Ordinary Shares of Royalty Pharma plc as a restricted stock unit award.

Summary

• Vlad Coric, a director of Royalty Pharma plc, received an award of 3,184 Class A Ordinary Shares on April 21, 2025.
• The shares were granted as restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan.
• The restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard practice of awarding stock to directors, aligning their interests with shareholders. There are no indications of negative implications.

Positives

• The award of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock units.

Industry Context

Stock awards to directors are a common practice in publicly traded companies to incentivize and align their interests with shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock awards, vary significantly across the pharmaceutical industry depending on company size, performance, and governance practices.
• Comparing Royalty Pharma's director compensation to peers like Gilead Sciences, Amgen, or AbbVie would provide a better understanding of whether this award is standard or exceptional.

Stakeholder Impact

• The stock award aligns the director's interests with those of the shareholders, potentially leading to better decision-making for the company.
• Employees may view the award as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Royalty Pharma, Director, Vlad Coric, Stock Award, Restricted Stock Units, RPRX, Equity Incentive Plan, Beneficial Ownership